We deliver GMP-aligned, process-driven facility design specifically engineered for end-to-end mRNA vaccine manufacturing, covering plasmid DNA amplification, in vitro transcription, mRNA purification, LNP formulation, sterile filling, and final packaging. Tailored to the highly sensitive, RNase-free, and aseptic requirements of mRNA production, our facility design fully complies with EMA Annex 1, FDA cGMP, PIC/S and ISPE biomanufacturing guidelines, ensuring strict environmental control, cross-contamination prevention, and consistent product stability.
Our specialized layout features functionally segregated zones for upstream nucleic acid production, midstream LNP nanoparticle formulation, and downstream aseptic filling. We implement dedicated RNase contamination control strategies, independent HVAC air handling systems, graded cleanroom classification, and strict differential pressure cascades to maintain unidirectional clean airflow. Closed fully-enclosed process transfer systems minimize human intervention and eliminate exogenous contamination risks, which are critical for high-purity mRNA production.
The integrated utility system design includes high-purity water, pure steam, sanitized process piping, automated CIP/SIP systems, and continuous environmental monitoring for particles, microbes, temperature and humidity. We adopt BIM-based detailed engineering to optimize equipment layout, streamline material and personnel flow, and reduce dead spaces and operational bottlenecks.
Our design solutions support clinical-scale pilot production lines and large-scale commercial mRNA vaccine factories, as well as GMP upgrades of existing bioprocessing facilities. Every design module is audit-ready, risk-based and fully validated, enabling fast regulatory approval, stable batch-to-batch consistency, and accelerated time-to-market for mRNA vaccine products.
